RESULTS	There was an associated significant reduction in pad use ( reduced by -1.21 vs. -0.80 ; p = 0.0089 ) ; the mean result for solifenacin 5 mg amounted to a 51 % additional improvement over that of tolterodine ER 4 mg .\